tiprankstipranks
Advertisement
Advertisement

OCS Stock Latest News

Oculis initiated with a Buy at Guggenheim
The FlyOculis initiated with a Buy at Guggenheim
11h ago
OCS
Oculis price target raised to $42 from $38 at JPMorgan
PremiumThe Fly
Oculis price target raised to $42 from $38 at JPMorgan
3d ago
OCS
Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility
PremiumCompany Announcements
Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility
6d ago
6K
OCS
Oculis price target raised to $47 from $44 at H.C. Wainwright
PremiumThe Fly
Oculis price target raised to $47 from $44 at H.C. Wainwright
9d ago
OCS
Oculis price target raised to $44 from $43 at BofA
PremiumThe Fly
Oculis price target raised to $44 from $43 at BofA
9d ago
OCS
Oculis reports Q1 EPS (49c), consensus (41c)
PremiumThe FlyOculis reports Q1 EPS (49c), consensus (41c)
9d ago
OCS
Oculis Reports Strong Liquidity in Q1 2026 Unaudited Results
Premium
Company Announcements
Oculis Reports Strong Liquidity in Q1 2026 Unaudited Results
9d ago
6K
OCS
Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes
Premium
Company Announcements
Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes
19d ago
OCS
Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing
PremiumCompany Announcements
Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing
26d ago
OCS
Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session
PremiumCompany Announcements
Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session
29d ago
6K
OCS
Oculis Buy Rating Reiterated on De-Risked Phase 3 DIAMOND Program and Blockbuster Potential of Topical DME Therapy OCS-01
PremiumRatings
Oculis Buy Rating Reiterated on De-Risked Phase 3 DIAMOND Program and Blockbuster Potential of Topical DME Therapy OCS-01
1M ago
OCS
Oculis Holding: Needham Conference Visibility Reinforces Buy Rating and Upside Potential
PremiumRatings
Oculis Holding: Needham Conference Visibility Reinforces Buy Rating and Upside Potential
1M ago
OCS
Three new option listings on March 17th
PremiumThe FlyThree new option listings on March 17th
2M ago
OCS
GBFH
Oculis price target raised to $50 from $40 at Stifel
Premium
The Fly
Oculis price target raised to $50 from $40 at Stifel
3M ago
OCS
Oculis Files 2025 Financials and Renews $100 Million ATM Program
Premium
Company Announcements
Oculis Files 2025 Financials and Renews $100 Million ATM Program
3M ago
6K
OCS
Oculis files automatic mixed securities shelf
PremiumThe Fly
Oculis files automatic mixed securities shelf
3M ago
OCS
Oculis price target raised to $44 from $42 at H.C. Wainwright
PremiumThe Fly
Oculis price target raised to $44 from $42 at H.C. Wainwright
3M ago
OCS
Oculis: Advancing Late-Stage Ophthalmology Pipeline Drives Upside and Supports Buy Rating
PremiumRatings
Oculis: Advancing Late-Stage Ophthalmology Pipeline Drives Upside and Supports Buy Rating
3M ago
OCS
Oculis: Strengthened Balance Sheet and Advancing Late-Stage Pipeline Support Buy Rating and Higher $40 Target Ahead of 2026 Pivotal Readouts
PremiumRatings
Oculis: Strengthened Balance Sheet and Advancing Late-Stage Pipeline Support Buy Rating and Higher $40 Target Ahead of 2026 Pivotal Readouts
3M ago
OCS
Oculis Posts 2025 Results, Extends Cash Runway and Advances Late-Stage Ophthalmology Pipeline
PremiumCompany AnnouncementsOculis Posts 2025 Results, Extends Cash Runway and Advances Late-Stage Ophthalmology Pipeline
3M ago
6K
OCS
Oculis reports Q4 EPS (CHF 0.42c) vs. (CHF 0.67) last year
Premium
The Fly
Oculis reports Q4 EPS (CHF 0.42c) vs. (CHF 0.67) last year
3M ago
OCS
Oculis Holding Ag (OCS) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Oculis Holding Ag (OCS) Q4 Earnings Cheat Sheet
3M ago
OCS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >